These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 15378521)

  • 1. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
    Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
    BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
    Bangma CH; Wildhagen MF; Yurdakul G; Schröder FH; Blijenberg BG
    BJU Int; 2004 Apr; 93(6):720-4. PubMed ID: 15049979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Measurement and analysis of different serum PSA in patients with benign prostatic hyperplasia].
    Li Y; Xu P; Zhang PA; Su HW; Zhang J
    Zhonghua Nan Ke Xue; 2003 Aug; 9(5):361-3, 366. PubMed ID: 14513646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
    Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.